Search clinical trials for: intravesical BCG

Total 597 results

H. Lee Moffitt Cancer Center and Research Institute
Celgene Corporation

Completed

Oral Lenalidomide and Intravesical BCG for Therapy of Bladder Cancer

Bladder Cancer

United States
University of Colorado, Denver
Rutgers Cancer Institute of New Jersey

Terminated

Sequential Intravesical Bacillus Calmette-Guérin and Electromotive Mitomycin-C After Transuretheral Resection

Bladder Carcinoma

United States
Anchiano Therapeutics Israel Ltd.

Completed

Phase 2b, Trial of Intravesical DTA-H19/PEI in Patients With Intermediate-Risk Superficial Bladder Cancer

Superficial Bladder Cancer

Israel, United States
Theralase Inc.
University Health Network, Toronto; WCCT Global; Medelis Inc.

Completed

Intravesical Photodynamic Therapy (PDT) in BCG Refractory High-Risk Non-muscle Invasive Bladder Cancer (NMIBC) Patients

Non-Muscle Invasive Bladder Cancer (NMIBC) Refractory to BCG

Canada
M.D. Anderson Cancer Center
Bristol-Myers Squibb

Terminated

Trial of Anti-PD-1 (Nivolumab) in Bladder Cancer Patients Recently Treated With Intravesical BCG Immunotherapy

Bladder Cancer

United States
Memorial Sloan Kettering Cancer Center
New York University; Novartis Pharmaceuticals; University of Hawaii

Completed

RAD001 and Intravesical Gemcitabine in BCG-Refractory Primary or Secondary Carcinoma In Situ of the Bladder

Bladder Cancer

United States
Bioniche Life Sciences Inc.

Terminated

Efficacy and Safety Evaluation of EN3348 (Mycobacterial Cell Wall-DNA Complex [MCC]) as Compared With Mitomycin C in the Intravesical Treatment of Subjects With BCG Recurrent/Refractory Non-muscle Invasive Bladder Cancer (EMBARC-RF)

Carcinoma in Situ | Neoplasm Recurrence, Local | Bladder Neoplasm | Mycobacterium | Transitional Cell, Carcinoma

United States, Canada, Poland, Germany, Netherlands, United Kingdom
FKD Therapies Oy

Completed

Intravesical Administration of rAd-IFN/Syn3 in Patients With BCG-Refractory or Relapsed Bladder Cancer

Superficial Bladder Cancer
Ankara Training and Research Hospital

Completed

In the Prediction of Recurrence and Progression of NMIBC; EORTC or CUETO or Both?

Disease Progression | Bladder Cancer | Recurrent Bladder Cancer
Mansoura University

Unknown

Solifenacin, Levofloxacin or Lornoxicam, Which Is Ideal for Management of Intravesical Instillation BCG Side Effects?

Non-Muscle-invasive Bladder Cancer (NMIBC) | Bacillus Calmette-Guerin (BCG) Cystitis | Intra-vesical Instillation

Egypt
M.D. Anderson Cancer Center
Flight Attendant Medical Research Institute

Completed

Markers of Response to Intravesical Bladder Cancer Therapy

Bladder Cancer

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI); FKD Therapies Oy of Finland

Completed

1B Intravesical Administration of SCH 721015 (Ad-IFNa) in Admixture With SCH 209702 (Syn3) for The Treatment of BCG Refractory Superficial Bladder Cancer

Bladder Cancer

United States
Bioniche Life Sciences Inc.

Completed

Mycobacterial Cell Wall-DNA Complex in Treatment of BCG-refractory Patients With Non-muscle Invasive Bladder Cancer

Bladder Neoplasms

Canada, United States
King Faisal Specialist Hospital & Research Center

Completed

Phase II Trial of Concurrent Administration of Intravesical BCG & Interferon in the Treatment and Prevention of Recurrence of Superficial Transitional Carcinoma of the Urinary Bladder

Transitional Carcinoma of Urinary Bladder
The University of Texas Health Science Center at...

Completed

Phase I Mitomycin Combined With Bacillus Calmette-Guérin (BCG) for Bladder Cancer

Urinary Bladder Neoplasm

United States
Memorial Sloan Kettering Cancer Center
Weill Medical College of Cornell University; New York Presbyterian Hospital

Terminated

Mitomycin C Versus Bacillus Calmette-Guerin in the Intravesical Treatment of Non-Muscle-Invasive Bladder Cancer Patients

Bladder Cancer

United States
Endo Pharmaceuticals

Completed

Intravesical AD 32 (Valrubicin) in Patients With Carcinoma in Situ (CIS) of the Bladder Who Have Failed or Have Recurrence Following Treatment With Bacillus Calmette-guerin (BCG) (Bladder Cancer)

Carcinoma in Situ | Bladder Cancer

United States
Endo Pharmaceuticals

Terminated

A Prospective Registry to Assess the Effectiveness and Local Tolerability of Intravesical Valrubicin in Subjects With Non-muscle Invasive Bladder Cancer (NMIBC)

Bladder Cancer | CIS

United States
Medical Enterprises Europe B.V.

Terminated

Hyperthermia Treatment in Conjunction With Mitomycin C Versus Bacillus Calmette-Guérin Immunotherapy (BCG) for Superficial Bladder Cancer

Neoplasms | Urologic Neoplasms | Neoplasms by Site | Urologic Diseases | Urinary Bladder Diseases | Urinary Bladder Neoplasms | Urinary Bladder Cancer | Malignant Tumor of Urinary Bladder

Austria, Israel, Italy, Netherlands
Savino M. Di Stasi
University of Bari

Completed

Intravesical Natural Baobab Oil in the Management of BCG-induced Lower Urinary Tract Symptoms (Baobab)

Lower Urinary Tract Symptoms | Superficial Bladder Cancer

Italy
Azienda Ospedaliera San Giovanni Battista
University of Turin, Italy; Universitätsklinikum Hamburg-Eppendorf; University...

Completed

The Impact of Intravesical Gemcitabine and 1/3 Dose Bacillus Calmette-Guerin on the Quality of Life in Superficial Bladder Cancer

Bladder Cancer

Italy
University of Rome Tor Vergata
University of L'Aquila

Completed

Sequential Bacillus Calmette-Guérin (BCG) and Electromotive Mitomycin-C Versus Bacillus Calmette-Guérin (BCG) Alone for High Risk Superficial Bladder Cancer (BCG/EMDA-MMC)

Bladder Cancer

Italy
Halozyme Therapeutics

Completed

Study of Immediate Post-Operative Intravesical Instillation of Chemophase® in Patients With Superficial Bladder Cancer (IPOP)

Superficial Bladder Cancer

United States
HaEmek Medical Center, Israel

Unknown

Changes in Prostate Specific Antigen Levels During Synergo Therapy-Intravesical Chemotherapy Instillations Combined With Hyperthermia

Bladder Cancer

Israel
University Of Perugia

Completed

Bacillus of Calmette and Guerin (BCG) Versus Gemcitabine For Intravesical Therapy In High Risk Superficial Bladder Cancer

Bladder Cancer

Italy
LanZhou University

Completed

Intravesical Epirubicin Plus BCG to Prevent the Recurrence of Transitional Cell Carcinoma of Bladder

Bladder Neoplasms
UNICANCER
Natera, Inc.

Not yet recruiting

Decreasing Treatment for Metastatic HER2-Positive Breast Cancer With Undectable Cancer Levels in Blood Tests. (HEROES)

Metastatic Breast Cancer | HER2-positive Breast Cancer
Fujian Medical University Union Hospital

Recruiting

Multicenter Clinical Trial on the Effectiveness and Safety of Instillation of BCG and Alternative BCG Protocols for Intermediate and High-risk Non-muscle Invasive Bladder Cancer

Urinary Bladder Neoplasms | Treatment Outcome | Neoplasm Recurrence, Local | Multicenter Study | Immunotherapy, Active | BCG Vaccine

China
European Organisation for Research and Treatment...

Not yet recruiting

Improvement of Quality of Life Through Supportive Treatments for Hormone Therapy - Related Symptoms in Women With Early Breast Cancer

Musculoskeletal Pain | Drug-Related Side Effects and Adverse Reactions | Breast Cancer Stage I | Breast Cancer Stage II | Breast Cancer Stage III | HER2-negative Breast Cancer | ER+ Breast Cancer
Vaneltix Pharma, Inc.
Prevail Infoworks, Inc

Not yet recruiting

Safety, Efficacy, and Frequency of Administration of VNX001 in the Treatment of Interstitial Cystitis / Bladder Pain Syndrome (IC/BPS)

Interstitial Cystitis | Bladder Pain Syndrome
National Cancer Center, Korea

Recruiting

The Clinical Effectiveness and Safety of Intravesical Mitomycin-C and Gemcitabine Sequential Therapy (IMGeS)

Bladder Cancer

Korea, Republic of
RemeGen Co., Ltd.

Not yet recruiting

To Evaluate the Safety, Efficacy, and Pharmacokinetics of Intravesical Instiliations of Disitamab Vedotin in Patients With High-risk Non-muscular Invasive Bladder Cancer (NMIBC) That Express HER2

High-risk Non-muscle Invasive Bladder Cancer

China
Ractigen Therapeutics.

Recruiting

A Study of RAG-01 in Patients With Non-muscle-invasive Bladder Cancer (NMIBC) Who Have Failed Bacillus Calmette Guérin (BCG) Therapy

Non-Muscle-Invasive Bladder Cancer (NMIBC)

Australia
Hualien Tzu Chi General Hospital

Not yet recruiting

Intravesical Platelet-rich Plasma Injection in Patients With Interstitial Cystitis/Bladder-A Retrospective Study

Safety and Effectiveness Between Intravesical Platelet-rich Plasma Injection in Patients With Interstitial Cystitis/Bladder

Taiwan
Chang Gung Memorial Hospital
DOTSPACE

Recruiting

First-In-Human Study of PDT to Detect IAH

Intra-Abdominal Hypertension

Taiwan
Women and Infants Hospital of Rhode Island

Not yet recruiting

Intravesical Gentamicin to Prevent Recurrent UTI

Recurrent Uti
UroGen Pharma Ltd.

Not yet recruiting

A Phase 3 Study of UGN-103 for Treatment of Patients With Low-grade Intermediate-risk Non-muscle Invasive Bladder Cancer (UTOPIA)

Bladder Cancer | Urothelial Carcinoma Bladder | Urothelial Carcinoma
Affiliated Cancer Hospital & Institute of Guangzhou...

Not yet recruiting

HIVEC in Patients With Non-Muscle-Invasive Bladder Cancer

Non-Muscle-Invasive Bladder Cancer
Boehringer Ingelheim

Recruiting

Beamion BCGC-1: A Study to Find a Suitable Dose of Zongertinib in Combination With Trastuzumab Deruxtecan or With Trastuzumab Emtansine and to Test Whether it Helps People With Different Types of HER2+ Cancer That Has Spread

Metastatic Breast Cancer | Esophageal Adenocarcinoma | Metastatic Gastric Adenocarcinoma | Gastroesophageal Junction Adenocarcinoma

United States
Janssen Research & Development, LLC

Recruiting

A Study to Evaluate TAR-210 Versus Single Agent Intravesical Cancer Treatment in Participants With Bladder Cancer (MoonRISe-1)

Non-Muscle Invasive Bladder Cancer

Israel, United States, United Kingdom
European Organisation for Research and Treatment...

Not yet recruiting

Radiotherapy for BCG-unresponsive Non-muscle-invasive Carcinoma in Situ (CIS) Bladder Cancer

Bladder Cancer
Josefin Eklöf

Recruiting

Live Vaccines and Innate Immune Training in COPD. (COPD-LIVE)

COPD | Trained Innate Immunity

Denmark
SUNHO（China）BioPharmaceutical CO., Ltd.

Not yet recruiting

A Study of IAP0971 in Combination With Bacillus Calmette Guerin in High Risk Non-muscular Invasive Bladder Cancer

Bladder Cancer
McGill University
Université de Montréal

Not yet recruiting

A Study to Assess the Safety, Tolerability, and Pharmacology of Darifenacin in Patients With ALS

Amyotrophic Lateral Sclerosis

Canada
Istituto Oncologico Veneto IRCCS
Fidia Farmaceutici s.p.a.

Not yet recruiting

A Study to Evaluate Efficacy and Safety of Hydeal Cyst® Intravesical Instillations in Patients Treated With Intravesical Chemotherapy or Immunotherapy in Non-muscle Invasive Bladder Cancer (Hydeal Cyst)

Non-muscle Invasive Bladder Cancer

Italy
University of Oxford

Recruiting

BCG Revaccination Study in Diabetic and Non-Diabetic Adults

Tuberculosis

United Kingdom
Chengdu CoenBiotech Co., Ltd
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University

Recruiting

Clinical Trial for Evaluating the Efficacy and Safety of BCG for Therapeutic Use in the Prevention of Postoperative Recurrence of Medium/High-risk Non-muscle Invasive Bladder Cancer (NMIBC)

Non-Muscle Invasive Bladder Cancer

China
University Hospital, Tours

Recruiting

Elastographic Analysis of Urothelial Bladder Tumours (SONURO)

Elastographic Measurement | Intravesical Pressure Measurement

France
Jiangsu Simcere Pharmaceutical Co., Ltd.
Shanghai Xianxiang Medical Technology Co., Ltd.

Recruiting

A Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of SIM0237 Alone or in Combination With BCG in NMIBC

Non-Muscle-Invasive Bladder Cancer (NMIBC)

China
Fudan University

Not yet recruiting

Disitamab Vedotin Combined With BCG Therapy in HER2-expressing High-risk Non-muscle Invasive Bladder Cancer

Non-muscle Invasive Bladder Cancer | HER-2 Protein Overexpression

3

Subscribe